<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3335">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399866</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000411</org_study_id>
    <nct_id>NCT01399866</nct_id>
  </id_info>
  <brief_title>Cognitive Remediation With D-Cycloserine</brief_title>
  <official_title>Cognitive Remediation With D-cycloserine to Improve Smoking Cessation Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One hundred seventy-five eligible participants will be enrolled with aim of randomizing 60
      to a double-blind, placebo-controlled trial of D-cycloserine added to cue-exposure treatment
      to prevent relapse to smoking. Subjects who sign an informed consent, meet inclusion
      criteria, and demonstrate response to cue reactivity at the screening visit, will either be:

        -  started on approximately 3 weeks of either nicotine replacement therapy (NRT) at a dose
           of either 14 or 21 mg/day or varenicline titrated to 1.0 mg bid; decision of which
           method to use to quit smoking will be based on participant choice as well as taking
           into account any medical contraindications to either therapy.

        -  evaluated to confirm abstinence from smoking. Recently abstinent participants referred
           by a smoking cessation clinic, PCP or self referred must have an expired air CO &lt; 10
           ppm to confirm abstinence.

      Subjects who are able to demonstrate 18-24 hours of abstinence prior to the first Cue
      Exposure Therapy Visit (CET I) will be eligible to be randomized to two visits of study
      medication and cue exposure treatment, spaced five to nine days apart. Subjects will
      complete 2 follow-up visits at 2-4 days and four weeks after the last CET visit. The entire
      study involves twelve visits and will last approximately ten weeks. For recently abstinent
      participants referred by a smoking cessation clinic, PCP or self referred, the study
      involves 7 visits (screening and baseline visit will be merged into one and there is no CBT
      component) and will last approximately 7 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking.</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants assigned to receive D-cycloserine + CET will achieve better maintenance of tobacco abstinence, as assessed with self-report and saliva cotinine measurements, than those who receive placebo + CET at week 6 follow up visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Skin Conductance</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (skin conductance) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Heart Rate</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (heart rate) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Electromyogram</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (electromyogram) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Craving</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less craving at the Post-Extinction Assessment than those who receive placebo + CET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of D-cycloserine + Cue-exposure Treatment on Attentional Bias Toward Smoking Cues</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less attentional bias (Smoking Stroop task) toward smoking cues at the Post-Extinction Assessment than those who receive placebo + CET</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 mg capsule,single dose, twice, one week apart, by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-cycloserine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg capsule,single dose, twice, one week apart, by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>2 single weekly doses, 50 mg capsule</description>
    <arm_group_label>D-cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have smoked an average of ≥ 10 cigarettes/day during the past 6
             months

          -  have expired air CO ≥ 10 ppm or urine cotinine ≥ 100 ng/mL

          -  meet DSM-IV criteria for nicotine dependence

          -  aged 18 - 65

          -  Recently abstinent participants referred by a PCP, smoking cessation clinic or self
             referred must have an expired air CO &lt; 10 ppm to confirm abstinence

        Exclusion Criteria:

          -  Severe or uncontrolled medical or psychiatric illness

          -  History of multiple hospitalizations within the last six months for an ongoing
             medical condition

          -  Any significant, current and unstable cardiovascular disease, end stage renal
             failure, severe COPD requiring oxygen, any current unstable neurological disease, a
             history of seizures or epilepsy, or a history of head trauma with lasting
             neurological sequelae, will be excluded for their safety.

          -  Major depressive episode, mania or mixed episode in the prior 6 months

          -  Lifetime history of psychosis, delusional disorder, organic mental disorder by DSM-IV
             criteria, or ongoing cognitive impairment will also be excluded for their safety,

          -  Current excessive use of alcohol (&gt;21 drinks/week in female subjects; &gt;28 drinks/week
             in male subjects)

          -  Current use of illicit drugs.

          -  Current steroid use, current, daily use of benzodiazepines, or participants who are
             unwilling to modify their benzodiazepine use will.

          -  Pregnant or breastfeeding women will be excluded, as well as women of childbearing
             potential who will not use a medically acceptable method of contraception (i.e. IUD,
             oral contraceptives).

          -  Participants who are deaf, blind, or experience any other significant sensory
             impairment that would preclude them from completing study procedures will also be
             excluded, as well as participants who are unable to understand study procedures or
             provide informed consent.

          -  Participants receiving isoniazid or ethionamide, or who have a known sensitivity to
             D-cycloserine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Eden Evins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Center For Addiction Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>July 19, 2011</firstreceived_date>
  <firstreceived_results_date>April 15, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>A. Eden Evins</investigator_full_name>
    <investigator_title>Director Center for Addiction Medicine</investigator_title>
  </responsible_party>
  <keyword>D-cycloserine</keyword>
  <keyword>Smoking cues</keyword>
  <keyword>Cognitive remediation</keyword>
  <keyword>physiologic reactivity</keyword>
  <keyword>craving</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred fifty participants were enrolled (signed consent), but only 98 were found eligible and started study procedures. Eighty one participants started smoking cessation CBT, and 62 finished and were randomized to receive either D-cycloserine or identical placebo added to exposure treatment to prevent relapse to smoking.</recruitment_details>
      <pre_assignment_details>Participants received their choice of nicotine patch or varenicline (0.5 mg per day for 3 days, 0.5 mg bid for 4 days, 1 mg bid for 4 wks) and weekly cognitive behavioral therapy for smoking cessation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
Placebo</description>
        </group>
        <group group_id="P2">
          <title>D-cycloserine</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
D-cycloserine: 2 single weekly doses, 50 mg capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>After 4 wks of smoking cessation treatment and CBT, participants who had 18 hrs of abstinence, smoking no cigarettes for at least 18 hrs and CO&lt;10ppm were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
Placebo</description>
        </group>
        <group group_id="B2">
          <title>D-cycloserine</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
D-cycloserine: 2 single weekly doses, 50 mg capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.1" spread="11.4"/>
                <measurement group_id="B2" value="48.4" spread="12.4"/>
                <measurement group_id="B3" value="47.7" spread="11.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking.</title>
        <description>Participants assigned to receive D-cycloserine + CET will achieve better maintenance of tobacco abstinence, as assessed with self-report and saliva cotinine measurements, than those who receive placebo + CET at week 6 follow up visits</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>50 mg capsule,single dose, twice, one week apart, by mouth
Placebo</description>
          </group>
          <group group_id="O2">
            <title>D-cycloserine</title>
            <description>50 mg capsule,single dose, twice, one week apart, by mouth
D-cycloserine: 2 single weekly doses, 50 mg capsule</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking.</title>
            <description>Participants assigned to receive D-cycloserine + CET will achieve better maintenance of tobacco abstinence, as assessed with self-report and saliva cotinine measurements, than those who receive placebo + CET at week 6 follow up visits</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Skin Conductance</title>
        <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (skin conductance) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Heart Rate</title>
        <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (heart rate) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Electromyogram</title>
        <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less physiologic (electromyogram) reactivity to smoking cues at the Post-Extinction Assessment than those who receive placebo + CET.</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Craving</title>
        <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less craving at the Post-Extinction Assessment than those who receive placebo + CET</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of D-cycloserine + Cue-exposure Treatment on Attentional Bias Toward Smoking Cues</title>
        <description>Recently abstinent smokers assigned to receive D-cycloserine + CET will have less attentional bias (Smoking Stroop task) toward smoking cues at the Post-Extinction Assessment than those who receive placebo + CET</description>
        <time_frame>Up to 6 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
Placebo</description>
        </group>
        <group group_id="E2">
          <title>D-cycloserine</title>
          <description>50 mg capsule,single dose, twice, one week apart, by mouth
D-cycloserine: 2 single weekly doses, 50 mg capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypersalivation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stiffness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressen mood</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. Eden Evins, MD, MPH. Director of the MGH-Harvard Center for Addiction Medicine</name_or_title>
      <organization>Massachusetts General Hospital - Harvard Medical School</organization>
      <phone>6176434679</phone>
      <email>a_eden_evins@hms.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
